A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis

详细信息    查看全文

• 作者：Do Seon Song ; Myeong Jun Song ; Si Hyun Bae ; Woo Jin Chung…
• 关键词：Hepatic arterial infusion chemotherapy ; Sorafenib ; Hepatocellular carcinoma ; Portal vein tumor thrombosis
• 刊名：Journal of Gastroenterology
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：50
• 期：4
• 页码：445-454
• 全文大小：509 KB
• 参考文献：1. Ferlay, J, Shin, HR, Bray, F, Forman, D, Mathers, C, Parkin, DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J cancer. 127: pp. 2893-2917 CrossRef
  2. Zhang, BH, Yang, BH, Tang, ZY (2004) Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130: pp. 417-422 CrossRef
  3. Llovet, JM, Bruix, J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37: pp. 429-442 CrossRef
  4. Pirisi, M, Avellini, C, Fabris, C, Scott, C, Bardus, P, Soardo, G (1998) Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study. J Cancer Res Clin Oncol 124: pp. 397-400 CrossRef
  5. Villa, E, Moles, A, Ferretti, I, Buttafoco, P, Grottola, A, Del Buono, M (2000) Natural history of inoperable hepatocellular carcinoma: estrogen receptors-status in the tumor is the strongest prognostic factor for survival. Hepatology 32: pp. 233-238 CrossRef
  6. Llovet, JM, Bustamante, J, Castells, A, Vilana, R, Ayuso Mdel, C, Sala, M (1999) Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 29: pp. 62-67 CrossRef
  7. Bruix, J, Sherman, M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: pp. 1020-1022 CrossRef
  Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56: pp. 908-943 CrossRef
  8. Omata, M, Lesmana, LA, Tateishi, R, Chen, PJ, Lin, SM, Yoshida, H (2010) Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Intl 4: pp. 439-474 CrossRef
  9. Cheng, AL, Kang, YK, Chen, Z, Tsao, CJ, Qin, S, Kim, JS (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: pp. 25-34 CrossRef
  10. Llovet, JM, Ricci, S, Mazzaferro, V, Hilgard, P, Gane, E, Blanc, JF (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J of Med 359: pp. 378-390 CrossRef
  11. Park, JY, Ahn, SH, Yoon, YJ, Kim, JK, Lee, HW, Lee do, Y (2007) Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 110: pp. 129-137 CrossRef
  12. Ando, E, Tanaka, M, Yamashita, F, Kuromatsu, R, Yutani, S, Fukumori, K (2002) Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 95: pp. 588-595 CrossRef
  13. Kim, HY, Kim, JD, Bae, SH, Park, JY, Han, KH, Woo, HY (2010) A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma. Korean J Hepatol 16: pp. 355-361 CrossRef
  14. Eun, JR, Lee, HJ, Moon, HJ, Kim, TN, Kim, JW, Chang, JC (2009) Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. Scand J Gastroenterol 44: pp. 1477-1486
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Gastroenterology
  Oncology
  Surgical Oncology
  Hepatology
  Internal Medicine
  Colorectal Surgery
  
• 出版者：Springer Japan
• ISSN：1435-5922

文摘

Background The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT). Methods A total of 110 patients were observed between February 2008 and May 2013 in seven Korean centers. Fifty patients were treated with HAIC, and 60 patients were treated with sorafenib. Results The disease control rate in the HAIC was significantly higher than that in the sorafenib group (p?p?=?0.214). The median overall survival (OS) was significantly longer in the HAIC group than in the sorafenib group (7.1 vs. 5.5?months, p?=?0.011). The median time to-progression (TTP) was also significantly longer in the HAIC group than in the sorafenib group (3.3 vs. 2.1?months, p?=?0.034). In the multivariate analysis, tumor diameter (?10?cm) and the absence of combined loco-regional treatment were significant prognostic factors influencing OS (p?=?0.002 and p?=?0.010, respectively) and TTP (p?=?0.017 and p?=?0.006, respectively). The treatment modality tended to be a significant prognostic factor for survival (p?=?0.052), but not for tumor progression (p?=?0.121). Conclusions HAIC is comparable with sorafenib in terms of OS and TTP in advanced HCC patients with PVTT. HAIC shows more favorable treatment responses compared with sorafenib. Therefore, HAIC might be an alternative treatment modality to sorafenib in advanced HCC patients with PVTT.